• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Renal

Fresenius preps $370m stock buyback

March 12, 2019 By Brad Perriello

Fresenius (NYSE:FMS) said today that it’s planning a stock buyback of up to $370 million worth of its own shares. Shareholders in the German renal care giant said its shareholders approved the roughly 6-million-share buyback in May 2016. The €330 million repurchasing plan is slated to run from today through May 10, Fresenius said. If fully […]

Filed Under: Featured, Wall Street Beat Tagged With: Fresenius, Renal

FDA approves Medtronic renal denervation trial in on-med patients

November 8, 2018 By Brad Perriello

Medtronic (NYSE:MDT) said today that the FDA approved a clinical trial of its Symplicity Spyral renal denervation device in patients who already take medication for their high blood pressure. Fridley, Minn.-based Medtronic said the three-year, 340-patient Spyral HTN-On Med sham-controlled study is designed to compare treatment with the Symplicity Spyral device and a sham procedure, randomized […]

Filed Under: Clinical Trials, Featured, Vascular Tagged With: Hypertension, Medtronic, Renal

Otsuka to acquire renal denervation firm ReCor Medical

July 10, 2018 By Brad Perriello

Otsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension. Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients […]

Filed Under: Mergers & Acquisitions, Ultrasound, Wall Street Beat Tagged With: Hypertension, Otsuka Holdings, ReCor Medical, Renal

Medtronic readies pivotal trial in renal denervation

August 28, 2017 By Brad Perriello

Medtronic (NYSE:MDT) said today that it’s ready for a run at FDA approval for renal denervation in treating high blood pressure, more than three years after the failure of a high-profile clinical trial. Back in January 2014, Fridley, Minn.-based Medtronic shocked medtech when it announced that the highly anticipated Symplicity HTN-3 trial, examining ablation of […]

Filed Under: Cardiovascular, Clinical Trials, Wall Street Beat Tagged With: Medtronic, Renal

ReCor Medical launches trial for Paradise renal denervation device

April 7, 2016 By Brad Perriello

ReCor Medical said today that it’s enrolled the 1st patients in the 292-patient Radiance-HTN study of its Paradise renal denervation device for treating hypertension. The blinded, randomized and sham-controlled trial is designed to evaluate the Paradise system in patients with essential hypertension taking 2 or fewer medications and patients with treatment-resistant hypertension on a minimum of 3 drugs. The trial […]

Filed Under: Cardiovascular, Clinical Trials Tagged With: Hypertension, ReCor Medical, Renal

Baxter launches trial for Vivia home hemodialysis system

March 15, 2016 By Brad Perriello

Baxter (NYSE:BAX) said today that it’s launching a clinical trial of the Vivia home hemodialysis device it’s co-developing with famed inventor Dean Kamen’s DEKA Research & Development Corp. The Vivia system is designed to provide shorter but more frequent dialysis rounds than conventional dialysis. The device has already won CE Mark approval in the European Union for use with […]

Filed Under: Clinical Trials, Dialysis Tagged With: Baxter, Renal

ReCor Medical to launch U.S. trial for Paradise renal denervation device

February 22, 2016 By Brad Perriello

ReCor Medical said today that it won an investigation device exemption from the FDA for a clinical trial of its Paradise renal denervation device for treating high blood pressure. Palo Alto, Calif., and Amsterdam-based ReCor said the 292-patient Radiance-HTN study, a blinded, randomized and sham-controlled trial, is designed to evaluate the Paradise system in patients with essential hypertension […]

Filed Under: Clinical Trials, Vascular Tagged With: Hypertension, ReCor Medical, Renal

Medtronic gets into renal care with Bellco acquisition

February 1, 2016 By Brad Perriello

Medtronic (NYSE:MDT) said today that it acquired renal care products make Bellco for an undisclosed amount and plans to fold it into a newly created renal care solutions division. Fridley, Minn.-based Medtronic said Mirandola, Italy-based Bellco makes devices designed to treat end-stage renal failure, multiple organ failure and sepsis, including dialyzers and chronic and acute dialysis machines. The […]

Filed Under: Dialysis, Mergers & Acquisitions, Wall Street Beat Tagged With: Bellco, Medtronic, Renal

Outset Medical raises $60m for home dialysis device

May 20, 2015 By Fink Densford

Outset Medical raises $60m for home dialysis device

Filed Under: Dialysis, Funding Roundup, News Well Tagged With: Dialysis, NxStage Medical Inc., Outset Medical, Renal

Renal denervation: Ablative Solutions wins CE Mark for chemical ablation catheter

May 13, 2015 By Fink Densford Leave a Comment

Hypertension: Ablative Solutions wins CE Mark for infusion ablation catheter

Ablative Solutions said it received CE Mark approval for its Peregrine infusion ablation catheter for treating uncontrolled hypertension. The company began testing Peregrine last year in Poland.

Filed Under: News Well Tagged With: Ablative Solutions, CE Mark, Hypertension, Renal

Renal denervation: Medtronic launches afib trial

April 30, 2015 By Brad Perriello Leave a Comment

Renal denervation: Medtronic launches afib trial

Medtronic (NYSE:MDT) today said it’s launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation.

Filed Under: News Well Tagged With: Cardiac Rhythm Management, Clinical Trials, Renal

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 17
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS